Results 11 to 20 of about 209,106 (262)

Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab

Cancer Management and Research, 2016
Jahnavi Gollamudi,1,* Jenny G Parvani,2,* William P Schiemann,3 Shaveta Vinayak3,4 1Department of Internal Medicine, 2Department of Biomedical Engineering, 3Case Comprehensive Cancer Center, Case Western Reserve University, 4Department of Hematology and ...
Gollamudi J, Parvani JG, Schiemann WP, Vinayak S   +3 more
doaj   +1 more source

Increasing Neoadjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients [PDF]

, 2020
Nasopharyngeal carcinoma (NPC) has radiosensitive and chemosensitive properties. The lack of radiotherapy devices makes concurrent chemoradiation difficult in Indonesia.
Muhtarum Yusuf, -, Andri Foris, -
core   +1 more source

A single arm phase II trial of neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle invasive transitional cell carcinoma of the urinary bladder [PDF]

, 2021
Introduction: Neoadjuvant cisplatin-based combination chemotherapy improves survival in muscle-invasive bladder cancer. However, response rates and survival remain suboptimal.
Pearson, Sylvia, Persad, Raj, Bravo, Alicia, Bahl, Amit, Masson, Susan, Perks, Claire, Ash-Miles, Janice, Dailami, Narges, Foulstone, Emily, Koupparis, Anthony, Challapalli, Amarnath, Holly, Jeff, Abdelaziz, Ahmed, Oxley, Jon, Rowe, Edward, White, Paul   +15 more
core   +1 more source

A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial [PDF]

, 2013
Background: Neo-tAnGo, a National Cancer Research Network (NCRN) multicentre randomised neoadjuvant chemotherapy trial in early breast cancer, enroled 831 patients in the United Kingdom.
K Walland, N Fenwick, M Iddawela, E Provenzano, Walland, K., Abraham, J. (Janet), Grier, Anna, L Hiller, J Abraham, A Grier, Fenwick, Nicola, Bowden, S. (Sarah), Iddawela, M., Caldas, C., H M Earl, R Champ, S Bowden, J Dunn, Vallier, A. -L., Champ, R., Earl, Helena M., C Caldas, Dunn, Janet A., Hiller, Louise, A-L Vallier, Provenzano, E.   +25 more
core   +2 more sources

Breast cancer: Monitoring response to neoadjuvant chemotherapy using Tc-99m sestamibi scintimammography [PDF]

, 2003
Background: Aim of the study was to assess the value of scintimammography using Tc-99m sestamibi in the evaluation of tumor response to neoadjuvant chemotherapy.
Sommer, H., Keßler, M., Tiling, R., Brinkbäumer, K., Hahn, K., Untch, M., Linke, R.   +6 more
core   +1 more source

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer [PDF]

, 2013
Introduction: Recent data suggest that benefit from trastuzumab and chemotherapy might be related to expression of HER2 and estrogen receptor (ESR1). Therefore, we investigated HER2 and ESR1 mRNA levels in core biopsies of HER2-positive breast carcinomas
Jens Huober, Reinisch, Mattea, Sibylle Loibl, Silvia Darb-Esfahani, Michael Untch, Hans Tesch, Martin-Leo Hansmann, Jan C Brase, Knut Engels, Judith Prinzler, Keyur Mehta, Minckwitz, Gunter von, Brase, Jan C., Kronenwett, Ralf, Hansmann, Martin-Leo, Huober, Jens, Engels, Knut, Solbach, Christine, Tesch, Hans, Carsten Denkert, Denkert, Carsten, Gunter von Minckwitz, Bruno V Sinn, Loibl, Sibylle, Mattea Reinisch, Peter A Fasching, Sinn, Bruno V., Ralf Kronenwett, Christine Solbach, Prinzler, Judith, Mehta, Keyur, Fasching, Peter Andreas, Untch, Michael, Denkert, Carsten Michael, Darb-Esfahani, Silvia   +34 more
core   +2 more sources

Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction [PDF]

, 2013
Background: This phase I/II-trial assessed the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of neoadjuvant radiochemotherapy (RCT) with docetaxel and oxaliplatin in patients with locally advanced adenocarcinoma of the oesophagogastric ...
Klautke, Gunther, Galle, Peter R., Brenner, Baruch, Arnold, Dirk, Roessler, Hans-Peter, Thomaidis, Thomas, Schimanski, Carl Christoph, Schmidberger, Heinz, Rödel, Claus, Gockel, Ines, Möhler, Markus, Trarbach, Tanja, Lang, Hauke   +12 more
core   +1 more source

Ifosfamide with regional hyperthermia in soft-tissue sarcomas [PDF]

, 2003
For high-risk soft tissue sarcomas (HR-STS) of adults, new treatment strategies are needed to improve outcome with regard to local control and overall survival.
M. Schlemmer, Wendtner, Clemens-Martin, C.M. Wendtner, R.D. Issels, Schlemmer, M., Issels, Rolf-Dieter   +5 more
core   +1 more source

Supersensitive PSA-Monitored neoadjuvant hormone treatment of clinically localized prostate cancer: Effects on positive margins, tumor detection and epithelial cells in bone marrow [PDF]

, 1998
Objective: The present study was done to investigate the effects of supersensitive PSA-controlled inductive treatment on positive margins, detection of tumor and epithelial cells in bone marrow of 101 patients with untreated and clinically localized ...
Köllermann, J., Kaulfuss, U., Spitz, J., Enzmann, Th., Köllermann M. W., Feek, U., Martell, W., Kossiwakis, M.   +7 more
core   +1 more source

Current status and novel directions in triple negative breast cancer patients. Risk factors. Role of the platinum-based chemotherapy [PDF]

Romanian Journal of Medical Practice, 2016
Rationale. Breast cancer (BC) has been recognized to be the most common type of cancer in women all over the world. One of the most aggressive subtype of BC is the triple negative breast cancer (TNBC) which is defined by the absence of estrogen receptor (
Olivia IONESCU, Irina BALESCU, Nicolae BACALBASA   +2 more
doaj   +1 more source